Palisade Bio, Inc. (NASDAQ:PALI) Receives $16.00 Consensus Price Target from Brokerages

Palisade Bio, Inc. (NASDAQ:PALI) has been given an average recommendation of “Moderate Buy” by the six ratings firms that are covering the company, Marketbeat.com reports. One research analyst has rated the stock with a sell rating, four have assigned a buy rating and one has given a strong buy rating to the company. The average 1-year target price among analysts that have issued ratings on the stock in the last year is $16.00.

A number of brokerages recently weighed in on PALI. B. Riley began coverage on Palisade Bio in a research report on Friday, January 9th. They set a “buy” rating and a $7.00 price objective on the stock. Citigroup reaffirmed a “buy” rating on shares of Palisade Bio in a research report on Tuesday, November 11th. Clear Str upgraded shares of Palisade Bio to a “strong-buy” rating in a research note on Monday, December 29th. Weiss Ratings reissued a “sell (e+)” rating on shares of Palisade Bio in a research report on Thursday, January 22nd. Finally, Piper Sandler started coverage on shares of Palisade Bio in a report on Monday, December 29th. They issued an “overweight” rating and a $25.00 price target on the stock.

Palisade Bio Stock Down 7.5%

Shares of PALI stock opened at $1.49 on Monday. The firm has a market cap of $222.01 million, a price-to-earnings ratio of -0.70 and a beta of 1.43. Palisade Bio has a 52-week low of $0.53 and a 52-week high of $2.64. The company’s 50 day moving average is $1.96 and its 200 day moving average is $1.48.

Palisade Bio (NASDAQ:PALI) last posted its earnings results on Monday, November 10th. The company reported ($0.38) earnings per share for the quarter, missing analysts’ consensus estimates of ($0.32) by ($0.06). Analysts anticipate that Palisade Bio will post -12.43 EPS for the current fiscal year.

About Palisade Bio

Palisade Bio, Inc is a clinical?stage biotechnology company focused on pioneering localized immunotherapies for the treatment of cancer and inflammatory diseases. The company leverages a proprietary prodrug platform designed to activate therapeutic agents selectively within the tumor microenvironment or sites of inflammation. Its core strategy centers on stimulating the innate immune system via toll?like receptor 9 (TLR9) agonism to drive targeted immune responses while minimizing systemic exposure and toxicity.

The company’s lead product candidate, PDS0108, is an intratumoral TLR9 agonist prodrug currently in Phase 1/2 clinical trials for patients with advanced solid tumors.